Ebola

Vaccine results positive in first human trial

27 Nov, 2014

U.S. scientists say that the first human trial of an Ebola vaccine being developed by NIH’s National Institute of Allergy and Infectious Diseases and British pharmaceutical giant GlaxoSmithKline produced ‘positive’ results. The twenty healthy adults who are tested develop anti-Ebola antibodies and produce an immune response with no serious side effects. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases:

Based on these positive results from the first human trial of this candidate vaccine, we are continuing our accelerated plan for larger trials to determine if the vaccine is efficacious in preventing Ebola infection.

Add your comments below...